Skip to content

Tyra Biosciences, Inc. TYRA Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Incyte logo
IncyteINCY
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
UroGen Pharma logo
UroGen PharmaURGN
BridgeBio Pharma logo
BridgeBio PharmaBBIO
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
Nuvation Bio logo
Nuvation BioNUVB

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%
Enterprise value$1.73B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s deferred tax assets and other non-current assets?
Tyra Biosciences, Inc. (TYRA) reported deferred tax assets and other non-current assets of $9.89M in Q1 2026.
How has Tyra Biosciences, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
Tyra Biosciences, Inc.'s deferred tax assets and other non-current assets decreased by 5.3% year-over-year, from $10.44M to $9.89M.
What is the long-term trend for Tyra Biosciences, Inc.'s deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s deferred tax assets and other non-current assets has grown at a 238.1% compound annual growth rate (CAGR), from $21K to $9.27M.